date:Jun 18, 2013
nik said that Sofinnova has been a compatible business partner because of its extensive experience in the healthcare industry. She said that the investment firm has followed F.A.S.T. for more than a year and has supported the products development. She said that their presence, along with the advisory board featuring Peter Barton Hutt, the former general counsel for the Food and Drug Administration (FDA), has aided the tricky process of bringing a drug product into market; a different kind of cha